Last reviewed · How we verify

Nolvadex — Competitive Intelligence Brief

Nolvadex (tamoxifen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SERM (Selective estrogen receptor modulator). Area: Oncology.

marketed SERM (Selective estrogen receptor modulator) Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nolvadex (tamoxifen) — AstraZeneca (originally ICI). Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nolvadex TARGET tamoxifen AstraZeneca (originally ICI) marketed SERM (Selective estrogen receptor modulator) Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6 1977-12-30

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SERM (Selective estrogen receptor modulator) class)

  1. AstraZeneca (originally ICI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nolvadex — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: